Radioimmunotherapy of Small Cell Lung Carcinoma with the Two-Step Method Using a Bispecific Anti-Carcinoembryonic Antigen/Anti-Diethylenetriaminepentaacetic Acid (DTPA) Antibody and Iodine-131 Di-DTPA Hapten: Results of a Phase I/II Trial

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages

  Vuillez, Jean Philippe ^a   Kraeber Bodéré, Françoise ^b   Moro, Denis ^a   Bardiés, Manuel ^b   Douillard, Jean Yves ^b   Gautherot, Emmanuel ^c   Rouvier, Eric ^c   Barbet, Jacques ^c   Garban, Frederic ^a   Moreau, Philippe ^b   Chatal, Jean François ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Immunotech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; HAPTEN; IFOSFAMIDE; IODINE 131; MESNA; MONOCLONAL ANTIBODY; PENTETIC ACID MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DOSE RESPONSE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SMALL CELL; FEMALE; HAPTENS; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 18744424004     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Moro, D., Jacoulet, P., Quoix, E., Ranfang, E., Brambilla, E., Capron, F., Lagrange, J. L., Milleron, B., Lebeau, B., Ruffle, P., Riviere, A., Blanchon, F., Geraads, A., Depien'e, A., and the members of the “Groupe d'Oncologie de Langue Francaise.” Small-cell lung cancer: patients surviving longer than thirty months. Anticaner Res., 14: 301-304, 1994.
2. American Cancer Society. Cancer Statistics 1984. CA Cancer J. Clin., 34: 7-23, 1984.
3. Pignon, J. P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., Brodin, O., Joss, R., Kies, M. S., Lebeau, B., Onoshi, T., Osterlind, K., Tattersall, M. H. N., and Wagner, H. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med., 327: 1618-1624, 1992.
4. Gregor, A., Cull, A., Stephens, R. J., Kirkpatrick, J. A., Yarnold, J. R., Girling, D. J., Macbeth, F. R., Stout, R., and Machin, D. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur. J. Cancer, 33: 1752-1758, 1997.
5. Shields, T. W., Higgins, G. A., and Matthews, M. S. Surgical resection in the management of small cell carcinoma of the lung. J. Thorac. Cardiovasc. Surg., 84: 481-488, 1982.
6. Ihde, D. C. Chemotherapy of lung cancer. N. Engl. J. Med., 327: 1434-1441, 1992.
7. Souhami, R. L., and Law, K. Longevity in small-cell lung cancer. A report of the United Kingdom Coorcinating Committee for Cancer Research. Br. J. Cancer, 61: 584-589, 1990.
8. Lassen, U., Osterlind, K., Hansen, M., Dombernowsky, P., Bergman, B., and Hansen, H. Long-term survival in small-cell lung cancer: posttreatment characteristic in patients surviving 5 to 18+ years: an analysis of 1,714 consecutive patients. J. Clin. Oncol. 13: 1215-1220, 1995.
9. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
10. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., Glenn, S. D., and Wahl, R. L. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
11. Wahl, R. L., Zasadny, K. R., MacFartane, D., Francis, I. R., Ross, C. W., Estes, J., Fisher, S., Regan, D., Kroll, S., and Kaminski, M. S. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J. Nucl. Med., 39 (Suppl.): 21S-27S, 1998.
12. Press, O. W., Eary, J. F., Applebaum, F. R., Martin, F., Nelp, W., Glenn, S., Fisher, D., Porter, B., Matthews, D., Gooley, T., and Bernstein, I. D. Phase II trial of 131I -B1 (anti CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
13. Chatal, J. F., Peltier, P., Bardies, M., Chetanneau, A., Thedrez, P., Faivre-Chauvet, A., and Gestin, J. F. Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy? Eur. J. Nucl. Med., 19: 205-213, 1992.
14. Behr, T. M., Goldenberg, D. M., and Becker, W. S. Radioimmunotherapy of solid tumors: a review “of mice and men.” Hybridoma, 16: 101-107, 1997.
15. Le Doussal, J. M., Chetanneau, A., Gruaz-Guyon, A., Martin, M., Gautherot, E., Lehur, P. A., Chatal, J. F., Delaage, M., and Barber, J. Bispecific monoclonal antibody-mediated targeting of“ an indium-11 Ilabeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J. Nucl. Med., 34: 1662-1671, 1993.
16. Le Doussal, J. M., Gautherot, E., Martin, M., Barbet, J., and Delaage, M. Enhanced in vivo targeting of an asymetric divalent hapten to double antigen-positive mouse B cells with monoclonal antibody conjugate cocktails. J. Immunol., 146: 169-175, 1991.
17. Bardiès, M., Bardet, S., Faivre-Chauvet, A., Peltier, P., Douillard, J. Y., Mahé, M., Fiche, M., Lisbona, A., Giacalone, F., Meyer, P., Gautherot, E., Rouvier, E., Barbet, J., and Chatal, J. F. Bispecific antibody and iodine-131-lbeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J. Nucl. Med., 37: 1853-1859, 1996.
18. Le Doussal, J. M., Gruaz-Guyon, A., Martin, M., Gautherot, E., Delaage, M., and Barbet, J. Targeting of indium 11 l-labeled divalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res., 50: 3445-3452, 1990.
19. DeNardo, G. L., DeNardo, S. J., Macey, D. J., and Mills, S. L. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: S. C. Srivastava (ed.), Radiolabeled monoclonal antibodies for imaging and therapy, pp. 293-310. New York: Plenum Publishing Corp., 1988.
20. Loevinger, R., Budinger, T. F., and Watson, E. E. MIRD Primer for Absorbed Dose Calculations. New York: The Society of Nuclear Medicine, 1988.
21. DeNardo, G. L., Mahé, M. A., DeNardo, S. J., Macey, D., Mirick, G., Erwin, W., and Groch, M. Body and blood clearance and marrow radiation dose of 131I -Lym-1 in patients with B-cell malignancies. Nucl. Med. Commun., 14: 587-595, 1993.
22. Hansen, H. H. Management of small-cell cancer of the lung. Lancet, 339: 846-849, 1992.
23. Grant, S. C., Kostakoglou, L., Kris, M. G., Yeh, S. D. J., Larson, S. M., Finn, R. D., Oettgen, H. F., and Cheung, N. K. V. Targeting of small-cell lung cancer using the antiGD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur. J. Nucl. Med., 23: 145-149, 1996.
24. Kosterink, J. G. W., de Jonge, M. W. A., Smit, E. F., Piers, D. A., Kengen, R. A. M., Postmus, P. E., Shochat, D., Groen, H. J. M., The, H. T., and de Leij, L. Pharmacokinetics and scintigraphy of indium- 111-DTPA-MOC-31 in small-cell lung carcinoma. J. Nucl. Med., 36: 2356-2362, 1995.
25. Mijnheere, E. P., Boerman, O. C., Poels, L. G., Slobbe, R. L., van Eys, G. J. J. M., and Ramaekers, F. C. S. Pharmacokinetics, biodistribution and dosimetry of anti-NCAM monoclonal antibody RNL-1 and its fragments in experimental lung cancer. J. Exp. Clin. Cancer Res., 15: 1118, 1996.
26. Ordanel, D., Ledermann, J. A., Eagle, K., Pedley, R. B., Boxer, G., Ward, S. E., Olabiran, Y., and Bomanji, J. Biodistribution of a radiolabelled monoclonal antibody NY3DI 1 recognizing the neural cell adhesion molecule in turnout xenografts and patients with small-cell lung cancer. Br. J. Cancer, 77: 103-109, 1998.
27. Peltier, P., Curtet, C., Chatal, J. F., Le Doussal, J. M., Daniel, G., Aillet, G., Gruaz-Guyon, A., Barbet, J., and Delaage, M. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/ anti-indium-DTPA antibody and an indium-11 l-labeled DTPA dimer. J. Nucl. Med., 34: 1267-1273, 1993.
28. Vuillez, J. P., Moro, D., Brichon, P. Y., Rouvier, E., Brambilla, E., Barbet, J., Peltier, P., Meyer, P., Sarrazin, R., and Brambilla, C. Twostep immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-11 ilabeled DTPA dimer. J. Nucl. Med., 38: 507-511, 1997.
29. Gautherot, E., Le Doussal, J. M., Bouhou, J., Manetti, C., Martin, M., Rouvier, E., and Barbet, J. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J. Nucl. Med., 39:1937-1943, 1998.